NCT01508910 - Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina | Biotech Hunter

Enrollment

291

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Chronic Myocardial IschemiaRefractory Angina PectorisAdvanced Coronary Heart Disease

Interventions

BIOLOGICAL

Auto-CD34+ cells

10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells

BIOLOGICAL

Placebo: Diluent used to suspend Auto-CD34+ cells

10 intramyocardial injections of 0.2 mL per injection site of placebo

OTHER

Standard of care

Standard of care for refractory angina

Trial Locations (41)

Unknown

Birmingham

Gilbert

Phoenix

La Jolla

Los Angeles

Oxnard

San Diego

Stanford

Boynton Beach

Daytona Beach

Gainesville

Jacksonville

Miami

Orlando

Tampa

Atlanta

Augusta

Chicago

Iowa City

Louisville

New Orleans

Boston

Saginaw

Minneapolis

Rochester

Haddon Heights

Newark

New York

Charlotte

Durham

Cincinnati

Cleveland

Philadelphia

Pittsburgh

Germantown

Dallas

Houston

Salt Lake City

Seattle

Madison

Milwaukee